Reassessment of theTP53 mutation database in human disease by data mining with a library ofTP53 missense mutations
- 3 December 2004
- journal article
- databases
- Published by Hindawi Limited in Human Mutation
- Vol. 25 (1) , 6-17
- https://doi.org/10.1002/humu.20114
Abstract
TP53 alteration is the most frequent genetic alteration found in human cancers. To date, more than 15,000 tumors with TP53 mutations have been published, leading to the description of more than 1,500 different TP53 mutants (http://p53.curie.fr). The frequency of these mutants is highly heterogeneous, with 11 hotspot mutants found more than 100 times, whereas 306 mutants have been reported only once. So far, little is known concerning the biological significance of these rare mutants, as the majority of biological studies have focused on classic hotspot mutants. In order to gain a deeper knowledge about the significance of all of these mutants, we have cross‐checked each mutant of the TP53 mutation database for its activity, derived from a library of 2,314 TP53 mutants representing all possible amino acid substitutions caused by a point mutation. The transactivation activity of all of these mutant was analyzed with respect to eight transcription promoters [Kato S, et al., Proc Natl Acad Sci USA ( 2003 )100:8424–8429]. Although the most frequent TP53 mutants sustain a clear loss of transactivation activity, more than 50% of the rare TP53 mutants display significant activity. Analysis in specific types of cancer or in normal skin patches demonstrates a similar distribution of TP53 loss of activity, with the exception of melanoma, in which the majority of TP53 mutants display significant activity. Our data indicate that TP53 mutants represent a highly heterogeneous population with a large diversity in terms of loss of transactivation activity that could account for the heterogeneous tumor phenotypes and the difficulty of clinical studies. Hum Mutat 25:6–17, 2005.Keywords
This publication has 37 references indexed in Scilit:
- Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73Published by Elsevier ,2003
- Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 geneOncogene, 2003
- A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramerNature Structural & Molecular Biology, 2001
- Rescuing the function of mutant p53Nature Reviews Cancer, 2001
- p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elementsOncogene, 2001
- Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeastOncogene, 1998
- A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce ApoptosisMolecular and Cellular Biology, 1996
- A simple p53 functional assay for screening cell lines, blood, and tumors.Proceedings of the National Academy of Sciences, 1995
- Gain of function mutations in p53Nature Genetics, 1993
- Definition of a consensus binding site for p53Nature Genetics, 1992